

BILL SUMMARY
1st Session of the 60th Legislature

Bill No.:	HB2801
Version:	INT
Request Number:	11293
Author:	Rep. Marti
Date:	2/4/2025
Impact:	Medicaid Costs: \$5,053,253 - \$7,561,671

Research Analysis

HB 2801, as introduced, provides that the Oklahoma Health Care Authority must approve a prior authorization request for any FDA approved atypical antipsychotic not on the preferred drug list for the treatment and prevention of mood disorders with psychotic symptoms. Medications included under this must be available at the same parity to other branded medications in the same class. Approval will be based on if there was a trial and failure of an approved atypical antipsychotic in the last year or if the patient is stable on an atypical antipsychotic not on the preferred drug list.

Prepared By: Suzie Nahach

Fiscal Analysis

HB 2801 directs the Oklahoma Health Care Authority (OHCA) to approve prior authorization requests for any FDA atypical antipsychotic not on the preferred drug list for the treatment of mood disorders. Medications are to be available at parity to branded medications in the same class.

According to OHCA, the agency assumed that utilization would increase by at least the amount of denied or incomplete claims made by a PA for higher-tiered medications. This assumption was then multiplied by the average claim cost for Tier 2 and Tier 3 atypical medications, accounting for both fee-for-service and managed care, and annualized to calculate the total federal and state share impact. As a result, OHCA anticipates the state share will range from \$5,053,253 to \$7,561,671.

Prepared By: Alexandra Ladner, House Fiscal Staff

Other Considerations

None.